arrow Log In to View Account     |      
Johns Hopkins Medicine
Hopkins Logo


Save the Date

Click below to register.

Friday, December 6, 2019
Hilton Orlando

6001 Destination Parkway
Orlando, FL
Room: Orlando Ballroom 4-6

12:30 PM – 1:00 PM: Registration and Lunch
1:00 PM – 3:00 PM: Interactive Educational Activity

Presented by the Johns Hopkins School of Medicine.

Supported by an educational grant from Dova Pharmaceuticals.

Advances in understanding the pathophysiology of thrombocytopenia have led to the development of a new class of agent, thrombopoietin receptor agonists (TRAs), two of which were recently approved by the US Food and Drug Administration. These therapies have implications across a range of thrombocytopenias and disease states. TRAs overcome many limitations of the minimally effective conventional procedures used to manage patients with chronic liver disease who undergo elective surgical procedures. TRA also has implications for agents that have also recently emerged as a first- and second-line treatment strategies in patients with chronic thrombocytopenia, specifically immune thrombocytopenia purpura (ITP), and is emerging as a treatment strategy for chemotherapy-induced thrombocytopenia. Appropriate use of these agents in practice requires that treating clinicians are both up-to-date on the latest evidence-based literature regarding TRAs as part of thrombocytopenia management and proficient in implementing these treatments appropriately. As a result, there is a need for education specifically for hematologists and other healthcare professionals who treat patients with thrombocytopenia that focuses on the efficacy and safety of novel treatments, the pathophysiology of hemostatic mechanisms affected in liver disease and other pathologies, bleeding risk laboratory measures used to guide treatment-making decisions, and navigating guideline recommendations for the appropriate diagnosis and treatment strategies for patients with thrombocytopenia.

This symposium will provide hematology clinicians with the latest evidence on the clinical utility of thrombopoietin receptor agonists in the management of thrombocytopenia of varying etiologies. This symposium will also highlight strategies to apply newly learned evidence into clinical practice.

This activity is intended for hematologists, nurse practitioners, physician assistants, and nurses who treat and manage patients with thrombocytopenia associated with liver disease and/or primary ITP. No prerequisites required.

After attending this activity, the participant will demonstrate the ability to:
  • DESCRIBE hemostatic pathological processes contributing to bleeding/thrombosis in liver disease and available laboratory measures to assess coagulation.
  • EVALUATE the role efficacy and safety of second-generation recently approved TRAs in the management of thrombocytopenia in adults with chronic liver disease.
  • IDENTIFY strengths of currently approved TRAs and develop strategies to select a TRA based on patient and procedural factors.
  • ASSESS the potential of TRAs in the management of for managing chronic immune thrombocytopenia, chemotherapy-induced thrombocytopenia, and severe aplastic anemia.
The Johns Hopkins School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

Satish Shanbhag, MBBS, MPH, FACP (Chair)
Associate Professor of Medicine and Oncology
Johns Hopkins School of Medicine
Baltimore, Maryland

James B. Bussel, MD
Emeritus Professor of Pediatrics
Medicine and Obstetrics and Gynecology
Weill Cornell Medicine
New York, New York

There is no fee for this educational activity.

<img src="" alt="procced to pretest" border="0" />

Johns Hopkins Advanced Studies in Medicine (ISSN-1558-0334), is published by ASiM CE, LLC, d/b/a ASiM, PO Box 340, Somerville, NJ 08876. (908) 253-9001. Copyright ©2017 by ASiM CE, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of ASiM CE LLC.